[kellyhound]

Peutz-Jeghers syndrome is a rare, inherited genetic disorder characterized by the development of noncancerous growths called hamartomatous polyps in the gastrointestinal tract, alongside distinct dark-colored pigment spots on the skin and mucous membranes.

First described by Dutch physician Jan Peutz in 1921, PJS significantly increases a person's lifetime risk of developing various types of cancer.

Caused by mutations in the STK11 (LKB1) tumor suppressor gene on chromosome 19. It is inherited in an autosomal dominant pattern, meaning a child of an affected parent has a 50% chance of inheriting it, though about 30% of cases occur spontaneously without family history.

Flat, dark brown or blue-gray spots resembling freckles that typically appear in early childhood around the lips, inside the mouth (buccal mucosa), on the nose, and around the fingers or toes. These often fade during adulthood.

Multiple benign polyps (hamartomas) grow throughout the digestive tract, most commonly in the small intestine. These polyps can cause chronic bleeding, iron-deficiency anemia, abdominal pain and intussusception (a dangerous condition where part of the intestine folds into itself, causing a blockage).

While the polyps themselves are benign, individuals with PJS have up to an 85% lifetime risk of developing cancer by age 70. This includes elevated risks for colorectal, pancreatic, stomach, small intestine, breast, ovarian, cervical and testicular cancers.

Every cell in the human body relies on specific genes to act as brakes to prevent uncontrolled growth. In PJS, one of the most critical braking systems is permanently compromised.

The STK11 gene acts as a master tumor suppressor. It codes for a protein kinase that instructs cells when to grow, when to divide, and when to die.

When a person inherits PJS, they are born with a mutation in one copy of the STK11 gene in every single cell of their body (a germline mutation).

Over time, if the second, healthy copy of the gene inside a cell becomes damaged or lost (known as loss of heterozygosity), that cell completely loses its ability to control its own growth, paving the way for cancer.

Under normal conditions, the STK11 protein activates a metabolic fuel gauge called AMPK. AMPK acts as a crucial checkpoint: when a cell is stressed or low on energy, AMPK shuts down cell division.

Without functioning STK11, this checkpoint fails. The chain reaction results in the hyperactivation of the mTOR pathway.

mTOR is a powerful driver of protein synthesis and cell growth and when mTOR is permanently stuck in the on position, cells consume energy rapidly and divide uncontrollably.

This continuous, rapid cellular proliferation happens across multiple tissue types, explaining why the cancer risk is not limited to just one organ.

STK11 is vital for maintaining cell polarity, the structural organization that tells a cell which way is up or down and how to properly anchor itself within a tissue. When cell polarity is lost, the structural boundaries of tissues break down.

This makes it significantly easier for abnormal cells to misbehave, replicate out of order and eventually invade surrounding tissues.

Healthy cells are programmed to self-destruct if they accumulate severe genetic damage, a process called apoptosis. STK11 directly cooperates with other major proteins (like p53) to trigger this cellular suicide when things go wrong.

A mutated STK11 gene allows damaged, mutated cells to evade apoptosis, letting them survive, multiply and evolve into malignancies.

The tissues heavily affected by PJS, including the gastrointestinal tract, breasts, and reproductive organs, are composed of epithelial cells that naturally undergo rapid cellular turnover.

Because these organs are already constantly dividing and highly sensitive to hormonal signaling, the loss of STK11's growth-regulating brakes leaves them highly vulnerable to turning cancerous.

By age 20 the risk remains very low. Most medical emergencies at this age are driven by benign polyp blockages or intussusceptions, rather than cancer.

However by age 40 the cumulative cancer risk climbs to approximately 20% to 30%. By age 50 the risk approaches nearly 50% and by age 60 to 70 the lifetime risk reaches its peak at 76% to 93%.

Scientists are using tissue engineering to grow mini-gut models (organoids) directly from the cells of PJS patients. This allows researchers to test thousands of different drug combinations safely in a lab setting to see exactly which compounds stop PJS tumor cells from growing.

Nowadays TOR Inhibitors (e.g., Everolimus, Sirolimus) drugs are used to directly target and switch off the hyperactive mTOR pathway caused by the STK11 mutation. By blocking this pathway, the drugs act as a chemical brake to stop abnormal cells from multiplying.

Research shows these drugs drastically reduce the size and number of polyps in PJS models. They are also used to treat advanced PJS-related pancreatic and breast cancers.

[Mr.NoCredit]

Big flesh flower growing out of him/her.

There are more strange medical complications from simply being human. Crazy